Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioimmunoTherapy (PAGRITR)

R. De Santis, A. M. Anastasi, V. D'Alessio, A. Pelliccia, C. Albertoni, A. Rosi, B. Leoni, R. Lindstedt, F. Petronzelli, M. Dani, A. Verdoliva, A. Ippolito, N. Campanile, V. Manfredi, A. Esposito, G. Cassani, M. Chinol, G. Paganelli, P. Carminati

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT) method is based on intravenous, sequential administration of a biotinylated antibody, avidin/streptavidin and 90Y-labelled biotin. The hybridoma clone producing the monoclonal antitenascin antibody BC4, previously used for clinical applications, was found not suitable for further development because of the production of an additional, nonfunctional light chain. In order to solve this problem, the new cST2146 hybridoma clone was generated. The monoclonal antibody ST2146, produced by this hybridoma, having the same specificity as BC4 but lacking the nonfunctional light chain, was characterised. ST2146 was found able to bind human tenascin at an epitope strictly related, if not identical, to the antigenic epitope of BC4. It showed, compared to BC4, higher affinity and immunoreactivity and similar selectivity by immunohistochemistry. Biodistribution studies of biotinylated ST2146 and three other monoclonal antitenascin antibodies showed for ST2146 the highest and more specific tumour localisation in HT29-grafted nude mice. On the overall, ST2146 appears to be a good alternative to BC4 for further clinical devedopment of PAGRIT.

Original languageEnglish
Pages (from-to)996-1003
Number of pages8
JournalBritish Journal of Cancer
Volume88
Issue number7
DOIs
Publication statusPublished - Apr 7 2003

Fingerprint

Radioimmunotherapy
Hybridomas
Monoclonal Antibodies
Antibodies
Epitopes
Clone Cells
Tenascin
Light
Neoplasms
Streptavidin
Avidin
Biotin
Nude Mice
Intravenous Administration
Immunohistochemistry

Keywords

  • Antibody pretargeting
  • Monoclonal antibody
  • Tenascin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

De Santis, R., Anastasi, A. M., D'Alessio, V., Pelliccia, A., Albertoni, C., Rosi, A., ... Carminati, P. (2003). Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioimmunoTherapy (PAGRITR). British Journal of Cancer, 88(7), 996-1003. https://doi.org/10.1038/sj.bjc.6600818

Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioimmunoTherapy (PAGRITR). / De Santis, R.; Anastasi, A. M.; D'Alessio, V.; Pelliccia, A.; Albertoni, C.; Rosi, A.; Leoni, B.; Lindstedt, R.; Petronzelli, F.; Dani, M.; Verdoliva, A.; Ippolito, A.; Campanile, N.; Manfredi, V.; Esposito, A.; Cassani, G.; Chinol, M.; Paganelli, G.; Carminati, P.

In: British Journal of Cancer, Vol. 88, No. 7, 07.04.2003, p. 996-1003.

Research output: Contribution to journalArticle

De Santis, R, Anastasi, AM, D'Alessio, V, Pelliccia, A, Albertoni, C, Rosi, A, Leoni, B, Lindstedt, R, Petronzelli, F, Dani, M, Verdoliva, A, Ippolito, A, Campanile, N, Manfredi, V, Esposito, A, Cassani, G, Chinol, M, Paganelli, G & Carminati, P 2003, 'Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioimmunoTherapy (PAGRITR)', British Journal of Cancer, vol. 88, no. 7, pp. 996-1003. https://doi.org/10.1038/sj.bjc.6600818
De Santis, R. ; Anastasi, A. M. ; D'Alessio, V. ; Pelliccia, A. ; Albertoni, C. ; Rosi, A. ; Leoni, B. ; Lindstedt, R. ; Petronzelli, F. ; Dani, M. ; Verdoliva, A. ; Ippolito, A. ; Campanile, N. ; Manfredi, V. ; Esposito, A. ; Cassani, G. ; Chinol, M. ; Paganelli, G. ; Carminati, P. / Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioimmunoTherapy (PAGRITR). In: British Journal of Cancer. 2003 ; Vol. 88, No. 7. pp. 996-1003.
@article{8e6fd057fb4d46b0a463376cbe7b0c5c,
title = "Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioimmunoTherapy (PAGRITR)",
abstract = "The Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT) method is based on intravenous, sequential administration of a biotinylated antibody, avidin/streptavidin and 90Y-labelled biotin. The hybridoma clone producing the monoclonal antitenascin antibody BC4, previously used for clinical applications, was found not suitable for further development because of the production of an additional, nonfunctional light chain. In order to solve this problem, the new cST2146 hybridoma clone was generated. The monoclonal antibody ST2146, produced by this hybridoma, having the same specificity as BC4 but lacking the nonfunctional light chain, was characterised. ST2146 was found able to bind human tenascin at an epitope strictly related, if not identical, to the antigenic epitope of BC4. It showed, compared to BC4, higher affinity and immunoreactivity and similar selectivity by immunohistochemistry. Biodistribution studies of biotinylated ST2146 and three other monoclonal antitenascin antibodies showed for ST2146 the highest and more specific tumour localisation in HT29-grafted nude mice. On the overall, ST2146 appears to be a good alternative to BC4 for further clinical devedopment of PAGRIT.",
keywords = "Antibody pretargeting, Monoclonal antibody, Tenascin",
author = "{De Santis}, R. and Anastasi, {A. M.} and V. D'Alessio and A. Pelliccia and C. Albertoni and A. Rosi and B. Leoni and R. Lindstedt and F. Petronzelli and M. Dani and A. Verdoliva and A. Ippolito and N. Campanile and V. Manfredi and A. Esposito and G. Cassani and M. Chinol and G. Paganelli and P. Carminati",
year = "2003",
month = "4",
day = "7",
doi = "10.1038/sj.bjc.6600818",
language = "English",
volume = "88",
pages = "996--1003",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioimmunoTherapy (PAGRITR)

AU - De Santis, R.

AU - Anastasi, A. M.

AU - D'Alessio, V.

AU - Pelliccia, A.

AU - Albertoni, C.

AU - Rosi, A.

AU - Leoni, B.

AU - Lindstedt, R.

AU - Petronzelli, F.

AU - Dani, M.

AU - Verdoliva, A.

AU - Ippolito, A.

AU - Campanile, N.

AU - Manfredi, V.

AU - Esposito, A.

AU - Cassani, G.

AU - Chinol, M.

AU - Paganelli, G.

AU - Carminati, P.

PY - 2003/4/7

Y1 - 2003/4/7

N2 - The Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT) method is based on intravenous, sequential administration of a biotinylated antibody, avidin/streptavidin and 90Y-labelled biotin. The hybridoma clone producing the monoclonal antitenascin antibody BC4, previously used for clinical applications, was found not suitable for further development because of the production of an additional, nonfunctional light chain. In order to solve this problem, the new cST2146 hybridoma clone was generated. The monoclonal antibody ST2146, produced by this hybridoma, having the same specificity as BC4 but lacking the nonfunctional light chain, was characterised. ST2146 was found able to bind human tenascin at an epitope strictly related, if not identical, to the antigenic epitope of BC4. It showed, compared to BC4, higher affinity and immunoreactivity and similar selectivity by immunohistochemistry. Biodistribution studies of biotinylated ST2146 and three other monoclonal antitenascin antibodies showed for ST2146 the highest and more specific tumour localisation in HT29-grafted nude mice. On the overall, ST2146 appears to be a good alternative to BC4 for further clinical devedopment of PAGRIT.

AB - The Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT) method is based on intravenous, sequential administration of a biotinylated antibody, avidin/streptavidin and 90Y-labelled biotin. The hybridoma clone producing the monoclonal antitenascin antibody BC4, previously used for clinical applications, was found not suitable for further development because of the production of an additional, nonfunctional light chain. In order to solve this problem, the new cST2146 hybridoma clone was generated. The monoclonal antibody ST2146, produced by this hybridoma, having the same specificity as BC4 but lacking the nonfunctional light chain, was characterised. ST2146 was found able to bind human tenascin at an epitope strictly related, if not identical, to the antigenic epitope of BC4. It showed, compared to BC4, higher affinity and immunoreactivity and similar selectivity by immunohistochemistry. Biodistribution studies of biotinylated ST2146 and three other monoclonal antitenascin antibodies showed for ST2146 the highest and more specific tumour localisation in HT29-grafted nude mice. On the overall, ST2146 appears to be a good alternative to BC4 for further clinical devedopment of PAGRIT.

KW - Antibody pretargeting

KW - Monoclonal antibody

KW - Tenascin

UR - http://www.scopus.com/inward/record.url?scp=0038368984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038368984&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6600818

DO - 10.1038/sj.bjc.6600818

M3 - Article

C2 - 12671694

AN - SCOPUS:0038368984

VL - 88

SP - 996

EP - 1003

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 7

ER -